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Abstract
In 2006, the OPPERA project (Orofacial Pain: Prospective Evaluation and Risk Assessment) set out to identify risk factors for development 
of painful temporomandibular disorder (TMD). A decade later, this review summarizes its key findings. At 4 US study sites, OPPERA 
recruited and examined 3,258 community-based TMD-free adults assessing genetic and phenotypic measures of biological, psychosocial, 
clinical, and health status characteristics. During follow-up, 4% of participants per annum developed clinically verified TMD, although 
that was a “symptom iceberg” when compared with the 19% annual rate of facial pain symptoms. The most influential predictors of 
clinical TMD were simple checklists of comorbid health conditions and nonpainful orofacial symptoms. Self-reports of jaw parafunction 
were markedly stronger predictors than corresponding examiner assessments. The strongest psychosocial predictor was frequency of 
somatic symptoms, although not somatic reactivity. Pressure pain thresholds measured at cranial sites only weakly predicted incident 
TMD yet were strongly associated with chronic TMD, cross-sectionally, in OPPERA’s separate case-control study. The puzzle was 
resolved in OPPERA’s nested case-control study where repeated measures of pressure pain thresholds revealed fluctuation that 
coincided with TMD’s onset, persistence, and recovery but did not predict its incidence. The nested case-control study likewise 
furnished novel evidence that deteriorating sleep quality predicted TMD incidence. Three hundred genes were investigated, implicating 
6 single-nucleotide polymorphisms (SNPs) as risk factors for chronic TMD, while another 6 SNPs were associated with intermediate 
phenotypes for TMD. One study identified a serotonergic pathway in which multiple SNPs influenced risk of chronic TMD. Two other 
studies investigating gene-environment interactions found that effects of stress on pain were modified by variation in the gene encoding 
catechol O-methyltransferase. Lessons learned from OPPERA have verified some implicated risk factors for TMD and refuted others, 
redirecting our thinking. Now it is time to apply those lessons to studies investigating treatment and prevention of TMD.
Keywords: chronic pain, psychological stress, pain threshold, human COMT protein, gene-environment interaction, cohort studies
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Introduction
In 2004, the National Institutes of Health (NIH) sought propos-
als for a prospective cohort study to “identify the incidence of 
craniofacial pain and dysfunction and its risk factors.” Referring 
to the existing cross-sectional evidence, the NIH cited numer-
ous factors that “may be implicated” in the etiology of temporo-
mandibular disorder (TMD), including age, sex, stress, 
depression, somatic symptoms, orthodontic treatment, occlusal 
or masticatory dysfunction, extraction of third molars, facial 
trauma, and degenerative arthritis. The funding opportunity was 
effectively a rallying call to apply the full expanse of the bio-
psychosocial model (Engel 1977) to an epidemiologic study of 
painful TMD. In moving beyond prevailing biomechanical 
explanations of TMD, the funding opportunity responded to a 
call that research shift away “from chasing occlusal contacts” 
and toward “vulnerability alleles” (Stohler 2004). Controlling 
risk factors for TMD is a first step toward reducing health care 
costs, which are 60% greater for TMD patients than for primary 
health care patients (White et al. 2001).
The NIH subsequently funded a project entitled Orofacial 
Pain: Prospective Evaluation and Risk Assessment (OPPERA), 
which enrolled its first study participant in 2006. A wide array 
of putative risk factors was measured, ranging from genotypes 
to intermediate phenotypes of psychological distress and pain 
amplification to environmental influences and clinical aspects 
of TMD itself. One decade later with 4,346 participants 
enrolled, the project has produced a wealth of evidence about 
TMD in adults—verifying some previously implicated risk 
factors, refuting others, and casting new light on TMD etiol-
ogy. This review summarizes selected findings from OPPERA’s 
35 papers published to date and considers directions for future 
epidemiologic research into TMD.
Overview of OPPERA’s Component 
Studies and Methods
The OPPERA study population comprised community-based 
volunteers aged 18 to 44 y living at 4 US locations: Baltimore, 
MD; Buffalo, NY; Chapel Hill, NC; and Gainesville, FL. 
Between 2006 and 2013, 4,346 subjects were recruited through 
advertisements, emails, and flyers, yielding a sample that 
broadly reflected the United States’ main sociodemographic 
groups (Appendix Table 1). There were 3 study designs: a pro-
spective cohort study, a case-control study, and a nested case-
control study.
The prospective cohort study aimed to determine the inci-
dence rate of first-onset TMD. At the baseline visit, the 3,258 
enrollees were examined with the Research Diagnostic Criteria 
for TMD (Dworkin and LeResche 1992) to exclude any par-
ticipants with clinical TMD. Participants completed an exten-
sive array of psychosocial questionnaires; autonomic function 
and sensitivity to experimental pain were measured; and a 
blood sample was collected (Appendix Table 2). Follow-up 
occurred over a median 2.8-y period after enrollment when par-
ticipants completed quarterly health questionnaires to screen 
for symptoms of TMD. Those reporting symptoms were asked 
to return to research clinics where examiners repeated the oro-
facial examination, yielding 260 incident cases of first-onset 
TMD myalgia and/or arthralgia through May 2011 (Bair, 
Brownstein, et al. 2013).
Realizing that the prospective cohort study would require 
several years of follow-up, a case-control study of chronic 
TMD was undertaken by additionally recruiting 1,088 partici-
pants with chronic TMD (Slade et al. 2011). The case classifi-
cation required a history of facial pain for at least 5 d per month 
in the preceding 6 mo, together with examiner-verified myal-
gia and/or arthralgia. Chronic TMD cases completed the same 
baseline data collection procedures as enrollees in the prospec-
tive cohort study.
The third study design captured more detailed information 
from the 260 incident cases and from a sample of participants 
in the prospective cohort study who remained TMD free (n = 
196). In this nested case-control study design, controls were 
matched to incident cases according to time since enrollment, 
study site, and sex (Slade et al. 2014). Incident cases and 
selected controls repeated most of the data collection proce-
dures performed at enrollment. Six months later, they were 
asked to return to research clinics for a third visit where clini-
cal TMD examinations were repeated, along with most of the 
data collection procedures performed at preceding visits.
The study was reviewed and approved by the Institutional 
Review Boards of the OPPERA study sites.
Selected Findings
4% Annual Incidence: Just the Tip of the Iceberg
In the prospective cohort study, the incidence rate of first-onset 
TMD was 3.9% per annum (Slade, Bair, et al. 2013). In other 
words, for every 100 TMD-free people enrolled, nearly 4 indi-
viduals per year developed the condition. Their pain event was 
not fleeting: the threshold for incident case classification was 
≥5 d with TMD pain symptoms per month in ≥1 mo during a 
3-mo reporting period. Incident cases rated their average pain 
unpleasantness as “slightly annoying” and pain intensity as 
“very mild” or “mild,” using verbal descriptor scales (Gracely 
et al. 1978). Often, the condition persisted: when reexamined 
6 mo after TMD first developed, almost half (49%) of incident 
cases still had TMD.
Facial pain symptoms occurred early and often for many 
study participants, including some who never developed clini-
cal TMD (Slade, Sanders, et al. 2013). Overall, one-third of 
cohort members reported ≥1 symptom episodes (i.e., facial 
pain for ≥5 d per month for ≥1 mo during a 3-mo reporting 
period). Initial symptom episodes occurred at a rate of 18.8% 
per annum. The rate doubled during follow-up of those who 
had an initial episode, and it doubled again in follow-up of 
those with recurrent symptoms. The sheer number of symptom 
episodes represents a “symptom iceberg” in the community, so 
named because it represents subclinical suffering that rarely 
comes to the attention of health care providers, yet it portends 
substantially elevated risk for future symptoms.
1086 Journal of Dental Research 95(10) 
Demographics: Sex and Race Paradoxes
There were some unexpected demographic patterns in the dis-
tribution of orofacial pain. The rate of TMD symptoms was no 
greater in women than in men. Likewise, the incidence rate of 
clinically verified TMD was only marginally greater in women 
than men (hazard ratio = 1.3, P = 0.06). This contrasted with 
US population estimates from the National Health Interview 
Survey, where prevalence of TMD symptoms in women was 
twice that of men (Maixner et al. in press).
OPPERA’s findings of racial differences in incidence were 
also unexpected. The rate of TMD symptoms in African 
Americans was twice that of whites, and the rate of clinically 
verified TMD was 52% greater (hazard ratio = 1.5, P = 0.01). 
Yet, in the National Health Interview Survey, prevalence of 
facial pain symptoms in African Americans was half that of 
whites (Maixner et al. in press).
These seemingly discrepant findings are due in part to 
prevalence-incidence bias (Friedman et al. 1966), a form of 
selection bias affecting cross-sectional study designs. Because 
they measure health status at only 1 point in time, cross-sectional 
studies are more likely to record disease in incident cases whose 
disease persists than in those whose condition resolves quickly. 
The bias, in turn, affects demographic associations when persis-
tence varies according to demographics. This was seen in the 
nested case-control study: 6 mo after TMD onset, 54% of 
females versus 41% of males had persistent TMD. Also, TMD 
persisted in 61% of whites versus 35% of African Americans.
Somatic Symptoms: The Most Important 
Psychosocial Predictor of TMD Incidence
Frequency of somatic symptoms was the strongest psychosocial 
predictor of TMD incidence (Fillingim et al. 2013). The 
Pennebaker Inventory of Limbic Languidness asks about fre-
quency of multiple somatic symptoms—for example, running 
nose, fatigue, and dizziness. Participants with scores in the upper 
tercile (i.e., symptoms occurring at least monthly, on average) 
had approximately twice the incidence rate of TMD as partici-
pants with less frequent somatic symptoms. The finding that a 
high score was the most important predictor was based on results 
from a random forest modeling procedure that evaluated all 26 
psychosocial measures, quantifying the contribution of each one 
to the accuracy of predicting incident TMD. Much smaller con-
tributions were made from measures of psychological stress, 
anxiety, obsessive-compulsive feelings, and pain-coping strate-
gies (Fillingim et al. 2013). It was noteworthy, however, that 
reactivity to sensory stimuli, assessed with the Kohn Reactivity 
Scale, was not a significant univariate predictor of TMD.
Pain Thresholds: A Consequence of TMD,  
Not a Predictor of It
Many cross-sectional studies have reported greater sensitivity 
to experimental pain in TMD cases as compared with controls, 
even when sensitivity is measured at noncranial sites. This has 
been variously attributed to alterations in sensory, endocrine, 
inflammatory, and psychological processes (Lautenbacher et al. 
1994), with greatest credence given to central sensitization 
(Woolf 2011). The OPPERA case-control study likewise found 
that chronic TMD cases had greater sensitivity to pressure 
pain, heat, and pinprick stimuli than controls (Greenspan et al. 
2011). The strongest associations with chronic TMD were seen 
for pressure pain, with odds ratios ranging from 2.6 to 3.7 (P < 
0.001) for thresholds measured at the trapezius and temporalis 
muscles, respectively. However, only a few of those measures 
were also significant predictors of TMD incidence, and effect 
estimates were weak (i.e., hazard ratios ranging from 1.1 to 
1.2; Greenspan et al. 2013).
The puzzle was at least partly resolved by analyzing 
repeated measurements of pressure pain thresholds in the 
nested case-control study (Slade et al. 2014). In persistent 
TMD cases, mean thresholds reduced by 17% between enroll-
ment and TMD onset and did not change significantly thereaf-
ter (Fig. 1). In transient TMD cases, mean thresholds initially 
reduced by 15% (P < .001) between enrollment and the TMD 
onset but increased by 9% (P < .001) once clinical TMD had 
resolved. Thresholds in controls did not change significantly 
over time. In other words, pressure pain thresholds fluctuated 
in response to onset and remission of TMD but did not usefully 
predict such changes. We speculated that painful TMD repre-
sents a trigger that increases synaptic efficacy of neurons in 
Figure 1. Pressure pain thresholds fluctuate with, but do not predict, 
onset and persistence of painful temporomandibular disorder (TMD). 
Reprinted from Slade et al. (2014). Adjusted mean pressure pain 
thresholds pooled from 5 anatomic locations measured at 3 visits in each 
of 3 study groups: OPPERA nested case-control study of TMD incidence. 
After enrollment (visit 1), the first follow-up (visit 2) occurred when TMD 
first developed or the matched control was selected, varying from 0.2 to 
4.5 y after visit 1. The second follow-up (visit 3) occurred approximately 
8 mo after visit 2 (range = 6 to 15 mo). Data are from 72 persistent 
TMD cases who developed first-onset TMD at visit 2 that persisted at 
visit 3 (), 75 transient TMD cases who developed first-onset TMD 
at visit 2 that remitted at visit 3 (X), and 126 TMD-free controls (). 
Symbols represent P values testing the null hypothesis that the adjusted 
mean threshold at one visit is equal to the adjusted mean threshold at 
the preceding visit in the same study group: ‡P < 0.01; †0.01 < P < 0.05. 
*Reference values for chronic TMD are from Greenspan et al. (2011). 
OPPERA, Orofacial Pain: Prospective Evaluation and Risk Assessment.
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nociceptive pathways, including pathways that participate in 
enhanced central nervous system sensitization.
Genetic Associations: SNPs and Biological 
Pathways of Their Combined Effects
The OPPERA case-control study evaluated genetic associa-
tions with chronic TMD using a panel of 2,924 single-nucleo-
tide polymorphisms (SNPs) representing 358 genes involved 
in biological systems relevant to pain perception. Six SNPs had 
stronger-than-expected associations within the distribution of 
P values for all tested SNPs (Table 1). One SNP was in the 
glucocorticoid receptor gene, suggesting a contribution of the 
hypothalamic-pituitary-adrenal system to chronic TMD. Another 
SNP was in the serotonin receptor gene, supporting other stud-
ies indicating that the gene influences nociceptive and affec-
tive pathways. The other 4 SNPs had not previously been 
associated with pain in humans and therefore represented novel 
findings implicating yet other biologic processes involved in 
chronic TMD.
The prospective cohort of initially TMD-free individuals 
provided an opportunity to investigate genetic associations 
with intermediate phenotypes, defined as “measurable compo-
nents unseen by the unaided eye along the pathway between 
disease and distal genotype” (Gottesman and Gould 2003). 
Four SNPs had associations that exceeded the false discovery 
rate (Smith et al. 2013). One was in the gene encoding the 
alpha subunit of the voltage-gated sodium channel Nav1.1, 
which influences action potentials in sensory nerves. It was 
associated with nonspecific orofacial symptoms such as jaw 
stiffness and fatigue. The same intermediate phenotype was 
associated with variation in a gene, angiotensin I–converting 
enzyme, which is implicated in hypertension. Meanwhile, 
global psychological and somatic symptoms were associated 
with an SNP in the prostaglandin-endoperoxide synthase 1 
gene, also known as COX-1, which regulates nociception and 
inflammatory response. Psychological stress and negative 
affectivity were associated with variation in the gene encoding 
APP, amyloid beta (A4) precursor protein, which affects syn-
apse formation and neuronal plasticity. Finally, heat pain tem-
poral summation was associated with an SNP in the multiple 
PDZ domain protein gene, which influences G protein–coupled 
receptors involved in nociception and analgesia.
While individual SNPs provide important insights into eti-
ology, complex conditions such as TMD are likely influenced 
by combined effects of multiple SNPs operating through spe-
cific biological pathways. Pathway analysis is a bioinformatics 
procedure that combines gene-disease association signals from 
several sets of genes that regulate predefined cellular pathways 
(Elbers et al. 2009). OPPERA was 1 of 2 cohorts in a discov-
ery-and-replication strategy to identify genetically regulated 
pathways relevant to TMD. Two subtypes of chronic TMD 
cases were defined according to the presence or absence of 
additional widespread body palpation pain (Slade, Smith, et al. 
2013). Relative to controls, cases of TMD without widespread 
pain had enrichment of genetic associations in a serotonergic 
signaling pathway, a finding that remained statistically signifi-
cant when replicated in the OPPERA cohort (Fig. 2). The spec-
ificity of the association for localized TMD suggested that the 
pathway elicited local hyperalgesia through activation of 
peripheral serotonin receptors but was counteracted by an ade-
quate central serotonergic response mechanism that limits 
potential for more widespread pain.
COMT Genotype Modifies Effects of Stress on 
Sensitivity to Noxious Stimuli and Incidence of TMD
Two analyses focused on the gene catechol O-methyltransferase 
(COMT ) because of its previously reported association with 
Table 1. Tests for Genetic Association between SNPs and TMD-Related Outcome Measures.
Gene Definition SNP Minor Allele Effect Estimatea P Value
Outcome: Chronic TMDb
NR3C1 Glucocorticoid receptor rs2963155 G OR = 0.63 6.2E-05
HTR2A Serotonin 2A receptor rs9316233 G OR = 0.64 3.4E-04
CHRM2 Muscarinic cholinergic receptor 2 rs7800170 A OR = 0.72 6.2E-04
CAMK4 Calcium/calmodulin-dependent protein kinase 4 rs3756612 G OR = 1.51 6.4E-04
IFRD1 Interferon-related developmental regulator 1 rs728273 G OR = 1.38 1.2E-03
GRK5 G protein–coupled receptor kinase 5 rs12415832 A OR = 2.4 1.3E-03
 Outcome: Nonspecific orofacial symptomsc
SCN1A Voltage-gated sodium channel, type I rs6432860 A OR = 1.43 2.8E-05
ACE2 Angiotensin I–converting enzyme 2 rs1514280 A OR = 1.32 4.9E-05
 Outcome: Global psychological symptomsc
PTGS1 Prostaglandin-endoperoxide synthase 1 rs3842803 C β = −0.22 2.8E-06
 Outcome: Stress and negative affectivityc
APP Amyloid beta (A4) precursor protein rs466448 A β = 0.11 4.3E-05
 Outcome: Heat pain temporal summationc
MPDZ Multiple PDZ domain protein rs10809907 C β = 0.16 3.1E-05
SNP, single-nucleotide polymorphism; TMD, temporomandibular disorder.
aOR, odds ratio for codominant test for association with binary outcome measure. β, linear regression parameter estimate of change in z score 
transformation of outcome measure associated with each copy of the minor allele.
bSmith et al. (2011).
cSmith et al. (2013).
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experimental pain (Diatchenko et al. 2006) and clinical TMD 
(Diatchenko et al. 2005). Gene-environment interactions with 
psychological stress were investigated because of the known 
role of COMT in regulating catechol neurotransmitter catabo-
lism, a process critical to the stress response. While the 2 stud-
ies had noteworthy differences in pain and stress phenotypes 
selected for analysis, the findings were consistent in demon-
strating potential for COMT to modify the effect of psycho-
logical stress on pain.
One study using experimental pain as the dependent vari-
able evaluated cross-sectional associations of COMT haplo-
type, experimental stress, and the 2-way interactions (Meloto 
et al. 2015). Experimental pain was evoked through repeated 
thermal stimuli applied to the arm, and stress was reported on 
a rating scale of 0 to 100. Summary variables of overall pain 
and maximum pain rating were both positively associated with 
stress. Pain ratings were also greater in participants with haplo-
types coding for low-activity COMT, signifying impaired 
catabolism of catecholamines. Significant interaction also 
occurred whereby the genetic association with pain was more 
pronounced in participants who experienced lower levels of 
stress.
The other study investigated contributions of COMT haplo-
types to incidence of first-onset TMD in the prospective cohort 
study. The Perceived Stress Scale (Cohen et al. 1983) mea-
sured response to common psychological stressors at enroll-
ment and once every 3 mo during follow-up (Slade et al. 2015). 
Stress increased to a greater degree in incident cases as com-
pared with those who remained TMD free, although this effect 
was limited to participants with haplotypes coding for low-
activity COMT (Fig. 3). A Cox model with stress as a time-
varying covariate revealed a significant genetic interaction 
such that a postbaseline increase in stress more than doubled 
the rate of TMD in participants with low-activity COMT hap-
lotypes but not in participants with high-activity COMT 
haplotypes.
Oral Parafunction and TMJ Derangements: 
Patients Know Best
The clinical examination included assessments of tooth wear 
(an indicator of oral parafunction) and TMJ noises during jaw 
movement (indicators of internal joint derangement). In the 
case-control study, both indicators were associated with 
chronic TMD, with corresponding odds ratios of 2.3 and 3.4, 
respectively (Ohrbach et al. 2011). However, associations were 
markedly stronger with participant-reported measures. Participants 
reporting multiple parafunctional behaviors in the Oral Behaviors 
Checklist questionnaire (Markiewicz et al. 2006) had 16 times 
the odds of chronic TMD as participants who reported only a 
few. Likewise, the odds ratio associated with self-reported 
TMJ noises was 30.2. We commented, however, that these 
double-digit measures of effect were almost certainly biased, 
probably due to differential recall by TMD cases versus 
controls.
Greater emphasis was therefore given to findings from the 
prospective cohort study, which eliminated any effects of recall 
bias by assessing parafunction and joint noises at enrollment, 
before TMD developed. It turned out that effect measures were 
not only smaller but also statistically nonsignificant for both 
examiner-assessed measures of tooth wear and joint derange-
ment (Ohrbach et al. 2013). However, self-reported temporo-
mandibular joint noises remained a significant predictor of 
TMD incidence. To underscore the value of self-reported 
measures, the Oral Behaviors Checklist scale emerged as the 
strongest predictor of incident TMD among all clinical vari-
ables—both examiner assessed and self-reported. There was a 
clear threshold effect such that risk of TMD was elevated only 
in participants who reported multiple behaviors that occurred 
frequently. We speculated that this density of parafunctional 
behavior in initially TMD-free participants probably signified 
some form of central dysregulation, such as heightened motor 
Figure 2. Cellular pathways associated with localized 
temporomandibular disorder. From Slade, Smith, et al. (2013). Genes 
shown in blue are significantly associated with case status (P < 0.05). 
HTR2A, 5-hydroxytryptamine receptor 2A (OMIM 182135); HTR2C, 
5-hydroxytryptamine receptor 2C (OMIM 312861); MAPK1, mitogen-
activated protein kinase 1 (OMIM 176948); MAP2K1, mitogen-activated 
protein kinase 1 (OMIM 176872).
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activation, diminished motor inhibition, reduced propriocep-
tion, or persistent psychophysiologic reactivity.
Comorbid Conditions: Nonpainful Ones Also Matter
Another of the strongest risk factors for developing TMD was 
also one of the simplest to assess: a checklist of 20 health con-
ditions (e.g., abdominal pain, depression, ringing in the ears). 
In random forest modeling that considered multiple health sta-
tus measures, the checklist was the most important predictor of 
incident TMD (Sanders, Slade, et al. 2013). In some respects, 
this was not surprising, given good evidence from other studies 
that pain elsewhere in the body strongly predicts TMD (Von 
Korff et al. 1993; John et al. 2003). However, the checklist was 
a significant predictor after controlling for more specific, vali-
dated measures of similar constructs, such as the ROME mea-
sure of irritable bowel syndrome (Longstreth et al. 2006) and 
SCL-90-R depression scale (Derogatis 1994). Moreover, the 
majority of checklist items were not primarily painful and 
instead represent ill-defined “comorbid” conditions (Valderas 
et al. 2009), suggesting that they are consequences of underly-
ing mechanisms contributing to TMD and the comorbid condi-
tions. There was evidence that cigarette smoking might be one 
such risk factor. In multivariable modeling, it was associated 
with increased risk of TMD, even after adjusting for painful 
and nonpainful health conditions. Overall, the findings point to 
the importance of general indicators of poor health in predict-
ing TMD incidence, filling a gap identified in an earlier sys-
tematic review of TMD etiology that found insufficient 
evidence regarding the potential effects of comorbidities on 
TMD (Macfarlane et al. 2001).
Sleep and Sleep Breathing: The Relationship 
with TMD
It is well established that the relationship between pain and 
sleep is bidirectional: pain disturbs sleep, and poor sleep exac-
erbates pain. Only in recent years have more nuanced study 
designs determined that sleep impairment is a stronger predic-
tor of pain, rather than the converse (Finan et al. 2013). To 
explore sleep quality in OPPERA, the Pittsburgh Sleep Quality 
Index was administered at enrollment in the prospective cohort 
study. Analysis showed that for each standard deviation decre-
ment in sleep quality, the rate of first-onset TMD increased 
40% (Sanders, Slade, et al. 2013). Sleep quality was also moni-
tored over time when participants completed a sleep quality 
rating scale of 0 to 10 every 3 mo throughout follow-up. In 
those who developed TMD, sleep quality deteriorated progres-
sively leading up to TMD onset, independent of psychosocial 
stress and other major TMD predictors. By contrast, sleep 
quality remained stable in participants who remained TMD 
free (Fig. 4). We then examined the possibility, demonstrated 
elsewhere (Onen et al. 2001; Smith et al. 2007), that disturbed 
sleep induces pain development via increased sensitivity to 
experimental pain. We indexed the latter in the nested case-
control study using pressure pain threshold and average 
pinprick pain sensation at baseline as well as changes in each 
measure during follow-up. The findings of formal mediation 
analysis were null, meaning that sensitivity to pain did not 
mediate the relationship between sleep quality and first-onset 
TMD.
Another intriguing aspect of the sleep and pain relationship 
is sleep-disordered breathing. A loss of muscle tonicity during 
sleep leads to partial or complete closure of the upper airway 
and disordered sleep breathing. Obstructive sleep apnea is a 
Figure 3. Psychological stress increases in participants with low-activity 
catechol O-methyltransferase (COMT) diplotypes who develop first-
onset temporomandibular disorder (TMD) but not in other groups. From 
Slade et al. (2015). Adjusted mean Perceived Stress Scale (PSS) scores at 
4 time points for incident cases of first-onset TMD () and TMD-free 
controls (), stratified according to diplotypes of the gene encoding  
COMT: (A) incident cases (n = 96) and TMD-free controls (n = 90) 
with low-activity COMT diplotypes (HPS-APS, HPS-HPS, APS-APS, or 
HPS-LPS); (B) incident cases (n = 84) and TMD-free controls (n = 63) 
with high-activity COMT diplotypes (LPS-LPS or LPS-APS). The 4 periods 
were as follows: the day of the baseline visit, when all participants were 
TMD free; intermediate follow-up, the quarterly periods after enrollment 
but before the penultimate quarter; the penultimate follow-up, the 
quarterly period preceding the final quarter; and the final follow-up, the 
quarterly period that coincided with the clinical visit at which incident 
TMD was determined. Error bars represent ±1 standard error (se) of the 
adjusted mean. Data points denoted by a star () represent PSS scores 
that differ significantly (P < 0.05) from baseline for participants with the 
same case classification within the same stratum of COMT diplotype. low 
(LPS), average (APS), and high pain sensitive (HPS).
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severe form of sleep-disordered breathing. OPPERA asked 
questions at baseline about 4 cardinal obstructive sleep apnea 
signs/symptoms: loud snoring, daytime sleepiness, witnessed 
apnea, and hypertension. Compared with participants with 
none or 1 of these characteristics, participants with ≥2 symp-
toms had a 73% greater hazard of developing TMD (Sanders, 
Essick, et al. 2013).
Putting It All Together: Finding the  
Forest among the Trees
The prospective cohort study evaluated 202 phenotypic risk 
factors from 6 domains: sociodemographic, general health sta-
tus, pain sensitivity, cardiac autonomic function, and psycho-
logical and clinical orofacial characteristics. This called for 
novel methods of multivariable modeling that could identify 
independent contributions of each risk factor and rank their 
importance in predicting TMD (Bair, Ohrbach, et al. 2013). 
One approach used penalized Cox regression, and the other 
used random forest models. Both overcome bias arising in 
regular regression models when selecting or ranking variables. 
Random forest models have the additional benefit of modeling 
nonlinear effects of continuous variables on the rate of TMD. 
Findings from both methods were consistent in finding that 
health status variables made the greatest contribution to TMD, 
followed closely by variables from psychological and clinical 
orofacial domains (Table 2). There were much smaller inde-
pendent contributions from the sociodemographic, pain sensi-
tivity, and autonomic function domains.
A different method of multivariable data analysis was then 
applied to create a clinically applicable tool to classify people 
with or at risk of TMD (Bair et al. 2016). This called for data 
reduction so that prediction could be achieved through only a few 
measures that are feasible in clinical practice. Another requirement 
was that individuals be reliably and unambiguously classified into 
meaningful categories based on their risk profiles. The method 
Figure 4. Sleep quality worsens prior to onset of temporomandibular 
disorder (TMD) in incident cases while remaining unchanged for 
matched controls. Reproduced from Sanders et al. (2016). Sleep quality 
was rated on a scale of 0 to 10 (0 = worst sleep, 10 = best sleep) in 
questionnaires completed once every quarter during follow-up of 
first-onset TMD cases (n = 220) and controls (n = 193) in the OPPERA 
nested case-control study. The 4 periods on the horizontal axis refer 
to the following: the first quarter (i.e., 3 mo) after enrollment; the 
intermediate quarters, between the first and penultimate quarters; the 
penultimate quarter, 3 mo before the final quarter; and the final quarter, 
the 3-mo interval prior to the follow-up visit at which presence or 
absence of TMD was determined. Error bars represent ±1 standard 
error (se) of the adjusted mean. Estimates are adjusted for study site, 
sex, age in years, and race/ethnicity. Asterisk (*) signifies a statistically 
significant difference (P < 0.05) as compared with the first quarter in the 
same study group. OPPERA, Orofacial Pain: Prospective Evaluation and 
Risk Assessment.
Table 2. Putative Temporomandibular Disorder Risk Factors with the 
Largest Importance Scores.
Domain: Variable
Importance  
Score Rank
Autonomic  
 HRV: total power (color-word Stroop) 19.1 15
 Average mean arterial pressure (pain-affect 
Stroop)
16.2 17
 Average mean arterial pressure (color-word 
Stroop)
15.8 19
 Average heart rate—ECG (pain-affect Stroop) 12.6 22
 HRV: total power (pain-affect Stroop) 10.8 28
Clinical  
 Count of nonspecific orofacial symptoms 92.9 2
 Oral parafunction sum score (OBC) 66.0 5
 Could not open mouth wide in the last month 54.1 6
 No. of palpation sites with pain (right masseter) 50.0 8
 Ever had orthodontic procedures 29.3 12
Demographic  
 Age 51.6 7
 Marital status 44.7 9
 Race 25.1 13
 Lifetime US residence 12.4 23
 Satisfaction with financial situation 5.5 58
Health status  
 Count of 20 comorbid conditions 100.0 1
 Bodily pain (SF-12v2) 80.6 4
 General health (SF-12v2) 31.8 11
 No. of different types of headaches in the  
last year
16.1 18
 Sleep latency (PSQI) 12.7 21
Pain sensitivity  
 Pressure pain threshold (masseter) 5.8 53
 Heat pain ratings of 10 stimuli: area under 
curve (48 °C)
4.2 62
 Pressure pain threshold (trapezius) 3.7 66
 Thermal pain single stimulus rating (46 °C) 3.6 67
 Thermal pain single stimulus rating (48 °C) 3.5 68
Psychosocial  
 Somatic symptom reporting (PILL) 42.4 10
 Catastrophizing—magnification (PCS) 10.4 30
 EPQ Lie scale 9.9 31
 Anxiety (SCL-90-R) 9.7 32
 Mood—clearheaded/confused (POMS-Bi) 6.5 46
Reproduced from Bair, Ohrbach, et al. (2013).
ECG, electrocardiogram; EPQ, Eysenck Personality Questionnaire; 
HRV, heart rate variability; OBC, Oral Behaviors Checklist; PCS, Pain 
Catastrophizing Scale; PILL, Pennebaker Inventory of Limbic Languidness; 
POMS-Bi, Profile of Mood States: Bi-polar Form; PSQI, Pittsburgh Sleep 
Quality Index; SCL-90-R, Symptom Checklist-90-R; SF-12v2, Medical 
Outcomes Study Short Form 12 Item Version 2. 
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was supervised cluster analysis, and it reliably identified 3 
clusters based on distinctive risk factor profiles in each group—
“adaptive,” “pain sensitive,” and “global symptoms.” Cluster 
membership was strongly associated with odds of chronic 
TMD and with risk of developing first-onset TMD, thereby 
providing good evidence of predictive validity. Nearest cen-
troid models were then fit with only 4 variables, providing 
promise that individuals could be classified into clusters by a 
relatively small number of variables.
Limitations and Future Directions
Findings summarized here are limited to adults aged 18 to 44 y 
who have been followed for no more than 5 y, with TMD repre-
senting the primary pain outcome. Inevitably, loss to follow-up 
produced some problems with missing data, although analytic 
methods were identified to control bias (Bair, Brownstein, et al. 
2013). Genetic association studies to date have been limited to 
targeted genes, although a genome-wide association study is 
now underway, and a second wave of studies that began in 2013 
has broadened the scope of biomarkers to include RNA and pro-
tein expression. Those studies will also investigate other idio-
pathic pain conditions that overlap with TMD. Other limitations 
have been discussed elsewhere (Slade, Fillingim, et al. 2013).
Conclusion
The decade of research discoveries summarized above endorses 
the premise underlying the National Institute of Dental and 
Craniofacial Research’s call for studies of TMD etiology—
namely, that TMD is a complex disorder resulting from an 
interplay of causes from multiple genetic and environmental 
domains. Time adds another dimension, with several risk fac-
tors exerting influences for some years before TMD manifests 
and with some fluctuating as the condition develops and either 
progresses or remits.
This complex etiology can seem overwhelming when con-
sidering the clinical implications of these findings. However, 
we see several general themes that should be applied judi-
ciously to guide patient care. First, it is clear that TMD devel-
ops at a disproportionately high rate in people with relatively 
poor health, whether in the form of comorbid disease, other 
pain conditions, poor sleep quality, or cigarette smoking. 
Efforts to promote general health should therefore be sup-
ported as a method of primary prevention for TMD. Second, it 
is noteworthy that some of the strongest predictors of developing 
TMD are also the easiest to assess, including simple participant-
completed checklists. Third is the encouraging finding that 
even hundreds of risk factors can be distilled by rigorous appli-
cation of cluster analysis to reliably categorize participants into 
a few clinically relevant subgroups.
These findings also make it clear that there are distinct path-
ways of TMD etiology. For example, there appears to be interplay 
of central and peripheral nociceptive mechanisms that contribute 
to some manifestations of TMD, while other mechanisms reflect 
gene-environment interactions. Those pathways will be under-
stood more completely as new research is undertaken. Nonetheless, 
the general notion of distinct pathways—coupled with findings 
that biopsychosocial risk factors define distinct clusters of people 
with or at risk of TMD—supports the ideas underlying a precision 
medicine approach to treating TMD. That premise likewise 
requires testing through rigorous clinical research. Taken together, 
they represent fascinating opportunities for the next decade of 
TMD research.
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